0001685676-16-000002.txt : 20160929 0001685676-16-000002.hdr.sgml : 20160929 20160929093605 ACCESSION NUMBER: 0001685676-16-000002 CONFORMED SUBMISSION TYPE: SC 13G PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20160929 DATE AS OF CHANGE: 20160929 GROUP MEMBERS: STRONGBRIDGE BIOPHARMA PLC SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: Strongbridge Biopharma plc CENTRAL INDEX KEY: 0001634432 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 981130690 STATE OF INCORPORATION: L2 FILING VALUES: FORM TYPE: SC 13G SEC ACT: 1934 Act SEC FILE NUMBER: 005-89153 FILM NUMBER: 161908484 BUSINESS ADDRESS: STREET 1: 900 NORTHBROOK DRIVE, SUITE 200 CITY: TREVOSE STATE: PA ZIP: 19053 BUSINESS PHONE: (610) 254-9200 MAIL ADDRESS: STREET 1: 900 NORTHBROOK DRIVE, SUITE 200 CITY: TREVOSE STATE: PA ZIP: 19053 FORMER COMPANY: FORMER CONFORMED NAME: Cortendo AB DATE OF NAME CHANGE: 20150219 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: STOREBRAND ASSET MANAGEMENT AS CENTRAL INDEX KEY: 0001685676 IRS NUMBER: 000000000 STATE OF INCORPORATION: Q8 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G BUSINESS ADDRESS: STREET 1: PROFESSOR KOHTS VEI 9 CITY: LYSAKER STATE: Q8 ZIP: 1366 BUSINESS PHONE: 004722312997 MAIL ADDRESS: STREET 1: PROFESSOR KOHTS VEI 9 CITY: LYSAKER STATE: Q8 ZIP: 1366 SC 13G 1 SC-13Gpt.txt SBBPSTB UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ________)* Strongbridge Biopharma plc (Name of Issuer) Ordinary shares, par value $0,01 per share (Title of Class of Securities) G85347105 (CUSIP Number) (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) September 20, 2016 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedu* (x) Rule 13d-1(b) Rule 13d-1(c) Rule 13d-1(d) * The remainder of this cover page shall be filled out for a reporting person'* the subject class of securities, and for any subsequent amendment containi* disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be* Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subjec* Act but shall be subject to all other provisions of the Act (however, see the N* CUSIP No. G85347105 13G Page 2 of 5Pages Storebrand Asset Management AS 1. NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) XXXXXXXXXX 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions) (a) ? (b) ? 3. SEC USE ONLY 4. CITIZENSHIP OR PLACE OF ORGANIZATION NORWAY NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5. SOLE VOTING POWER 1 063 020 6. SHARED VOTING POWER 7. SOLE DISPOSITIVE POWER 1 063 020 8. SHARED DISPOSITIVE POWER 00,000 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1 063 020 10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions) ? 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 5,01 % 12. TYPE OF REPORTING PERSON (see instructions) IV CUSIP No. G85347105 13G Page 3 of 5 Pages Item 1. (a) Name of Issuer Strongbridge Biopharma plc (b) Address of Issuer?s Principal Executive Offices 900 Northbrook Drive. Suite 200,Trevose, PA 19053 Item 2. (a) Name of Person Filing Storebrand Asset Management AS (b) Address of the Principal Office or, if none, residence Professor Kohts vei 9. 1366 Lysaker, Norway (c) Citizenship Norway (d) Title of Class of Securities Ordinary shares, par value $ 0,01 per share (e) CUSIP Number G85347105 Item 3. If this statement is filed pursuant to 240.13d-1(b) or 240.13d-2(b)* filing is a: (a) ? Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o). (b) ? Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c). (c) ? Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c). (d) ? Investment company registered under section 8 of the Investment Company Act of* (e) ? An investment adviser in accordance with 240.13d-1(b)(1)(ii)(E); (f) ? An employee benefit plan or endowment fund in accordance with 240.13d-1(b)(* (g) ? A parent holding company or control person in accordance with 240.13d-1(b)(1)* (h) ? A savings associations as defined in Section 3(b) of the Federal DeposIT* (i) ? A church plan that is excluded from the definition of an investment company.* Investment Company Act of 1940 (15 U.S.C. 80a-3); (j) ? Group, in accordance with 240.13d-1(b)(1)(ii)(J). Item 4. Ownership. Provide the following information regarding the aggregate. number and percenta* issuer identified in Item 1. (a) Amount beneficially owned: 1 063 020 (b) Percent of class: 5,01% (c) Number of shares as to which the person has: (i) Sole power to vote or to direct the vote 1 063 020 (ii) Shared power to vote or to direct the vote. (iii) Sole power to dispose or to direct the disposition of 1 063020. (iv) Shared power to dispose or to direct the disposition of . Instruction. For computations regarding securities which represent a right to* 240.13d-3(d)(1). Item 5. Ownership of Five Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof* beneficial owner of more than five percent of the class of securities, check th* Instruction. Dissolution of a group requires a response to this item. Item 6. Ownership of More than Five Percent on Behalf of Another Person. Item 7. Identification and Classification of the Subsidiary Which Acquired th* the Parent Holding Company. Item 8. Identification and Classification of Members of the Group. Item 9. Notice of Dissolution of Group. Item 10. Certification. (a) The following certification shall be included if the statement is filed pursuan* By signing below I certify that, to the best of my knowledge and belief, the * and are held in the ordinary course of business and were not acquired and are* effect of changing or influencing the control of the issuer of the securities * connection with or as a participant in any transaction having that purpose o* (b) The following certification shall be included if the statement is filed pursuan* By signing below I certify that, to the best of my knowledge and belief, the* acquired and are not held for the purpose of or with the effect of changing or* the securities and were not acquired and are not held in connection with or* that purpose or effect. CUSIP No. G85347105 13G Page 5 of x5Pages After reasonable inquiry and to the best of my knowledge and belief, I cer* statement is true, complete and correct. 09/27/2016 Date /s/ Anne-Kristin Baltzersen Signature Anne-Kristin Baltzersen/Chief director Name/Title